AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33939696 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 218
Study 33280619 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 66
Study 33280619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrax (vestibular rehabilitation)
Number of subjects: 66
Study 33280619 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 36180035 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT combined with deep learning (DL) model
Number of subjects: 1049
Study 36180035 — intervention group
Group type: COMPARATOR
Intervention: T-SPOT alone
Number of subjects: 1049
Study 36180035 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT negative and DL classified as NTM-PD
Number of subjects: 1049
Study 36180035 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT positive and DL classified as PTB
Number of subjects: 1049
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists wearing face masks
Number of subjects: 480
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists practicing regular hand sanitization
Number of subjects: 480
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists maintaining adequate antibiotic stock supply
Number of subjects: 480
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic dispensing patterns
Number of subjects: 480
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics dispensed upon physician recommendation
Number of subjects: 480
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin dispensed to presumptive patients
Number of subjects: 480
Study 33559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combinations given to home-isolated patients
Number of subjects: 480
Study 32647023 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics (OA) alone
Number of subjects: 74
Study 32647023 — intervention group
Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 74
Study 35436890 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS care protocol
Number of subjects: 166
Study 35436890 — intervention group
Group type: COMPARATOR
Intervention: Traditional perioperative care protocol
Number of subjects: 166
Study 34707696 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 380
Study 34707696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 36215043 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased familiarity between medical residents and nurses (intervention group)
Number of subjects: 33
Study 36215043 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 33
Study 34110689 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 20
Study 34110689 — intervention group
Group type: COMPARATOR
Intervention: PIT (preputioplasty and intralesional triamcinolone)
Number of subjects: 20
Study 33494843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake assessment via 24-hour urine collection
Number of subjects: 479
Study 33494843 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium intake assessment via 24-hour urine collection
Number of subjects: 479
Study 33494843 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 479
Study 33494843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low potassium intake
Number of subjects: 479
Study 33494843 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of Na and K excretion with BMI and age
Number of subjects: 479
Study 32821503 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback rehabilitation (BF)
Number of subjects: 24
Study 35278847 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS education with biomechanical visualization
Number of subjects: 8
Study 35278847 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS education with behavioral skill training
Number of subjects: 8
Study 35278847 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS education‐only
Number of subjects: 8
Study 35278847 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 33387108 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with MMC
Number of subjects: 40
Study 33387108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed valve
Number of subjects: 40
Study 33387108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐Press Minishunt with MMC
Number of subjects: 40
Study 33387108 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode cyclophotocoagulation
Number of subjects: 40
Study 34702183 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane block (ESPB) with 40 ml of 0.5% Ropivacaine, divided into two equal volumes, injected at T8 level under ultrasound guidance.
Number of subjects: 72
Study 34702183 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration (WI) with a 40 ml bolus of 0.5% Ropivacaine infiltrated at the ports and minimally invasive wound.
Number of subjects: 72
Study 33219392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load (LGL) diet for 28 days
Number of subjects: 80
Study 33219392 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet for 28 days
Number of subjects: 80
Study 33219392 — intervention group
Group type: COMPARATOR
Intervention: Clinical lipid panel measures (total-, VLDL-, LDL-, HDL-cholesterol and triglycerides)
Number of subjects: 80
Study 36280027 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine plus propofol, cisatracurium, and sufentanil
Number of subjects: 100
Study 36280027 — intervention group
Group type: COMPARATOR
Intervention: Saline plus propofol, cisatracurium, and sufentanil
Number of subjects: 100
Study 33896234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current plus photobiomodulation
Number of subjects: 168
Study 33896234 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Number of subjects: 168
Study 33896234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 33896234 — intervention group
Group type: COMPARATOR
Intervention: Interferential current
Number of subjects: 168
Study 35841422 — intervention group
Group type: EXPERIMENTAL
Intervention: LB-102 (50, 100, 200, 400 mg single ascending dose; 150 mg/day multiple ascending dose)
Number of subjects: 64
Study 35841422 — intervention group
Group type: EXPERIMENTAL
Intervention: LB-102 (200 mg)
Number of subjects: 64
Study 35841422 — intervention group
Group type: EXPERIMENTAL
Intervention: LB-102 (100 mg QD, 75 mg BID, 100 mg BID)
Number of subjects: 64
Study 34023695 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated subcutaneous immunoglobulin therapy (fSCIG)
Number of subjects: 12
Study 35687377 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mg/day elemental iron supplementation as part of a prenatal multivitamin
Number of subjects: 60
Study 35687377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity as a modifier
Number of subjects: 60
Study 32712847 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide dressing applied after 3 weeks of exposure to POS (blood)
Number of subjects: 80
Study 32712847 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide dressing applied after 3 weeks of exposure to LED (Ledermix)
Number of subjects: 80
Study 32712847 — intervention group
Group type: COMPARATOR
Intervention: Control group NEG (empty)
Number of subjects: 80
Study 32712847 — intervention group
Group type: COMPARATOR
Intervention: Control group ODO (Odontopaste)
Number of subjects: 80
Study 32712847 — intervention group
Group type: EXPERIMENTAL
Intervention: Final restoration after Ca(OH)2 dressing
Number of subjects: 80
Study 32533948 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network applied to corneal topography raw data
Number of subjects: 3000
Study 36415169 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled tip guidewire
Number of subjects: 422
Study 36415169 — intervention group
Group type: COMPARATOR
Intervention: Straight tip guidewire
Number of subjects: 422
Study 36415169 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled tip guidewire for intrahepatic stricture
Number of subjects: 422
Study 36415169 — intervention group
Group type: COMPARATOR
Intervention: Straight tip guidewire for intrahepatic stricture
Number of subjects: 422
Study 36415169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both guidewires (standard vs. enhanced flexibility)
Number of subjects: 422
Study 33214082 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan + 5 FU/LV with dose modification (n=53)
Number of subjects: 93
Study 33214082 — intervention group
Group type: COMPARATOR
Intervention: Liposomal irinotecan + 5 FU/LV without dose modification (n=40)
Number of subjects: 93
Study 32092636 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cannabis use
Number of subjects: 207
Study 35861647 — intervention group
Group type: EXPERIMENTAL
Intervention: ECochG 'on' during CI surgery
Number of subjects: 85
Study 35861647 — intervention group
Group type: COMPARATOR
Intervention: ECochG 'off' during CI surgery
Number of subjects: 85
Study 33957657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (6 milliunits/min)
Number of subjects: 1003
Study 33957657 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose oxytocin (2 milliunits/min)
Number of subjects: 1003
Study 32790783 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver responsive behaviours score
Number of subjects: 857
Study 32790783 — intervention group
Group type: EXPERIMENTAL
Intervention: Child responsive behaviours score
Number of subjects: 857
Study 32790783 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-child interaction score
Number of subjects: 857
Study 35668461 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted suture technique
Number of subjects: 100
Study 35668461 — intervention group
Group type: COMPARATOR
Intervention: Continuous suture technique
Number of subjects: 100
Study 35668461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 35773147 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 8179
Study 35773147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study 34508116 — intervention group
Group type: EXPERIMENTAL
Intervention: BeBo Concept exercise program (6-week physical therapy)
Number of subjects: 56
Study 34508116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 56
Study 36153027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app providing digitalised home exercises (Virtual Training app)
Number of subjects: 156
Study 36153027 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise therapy (standard treatment, 2 weekly sessions)
Number of subjects: 156
Study 36140045 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-SRP with Azithromycin (AZM)
Number of subjects: 51
Study 36140045 — intervention group
Group type: COMPARATOR
Intervention: Control group (supragingival calculus removal and oral hygiene instructions)
Number of subjects: 51
Study 33177133 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative Expressive Arts-based Storytelling (CrEAS) programme
Number of subjects: 111
Study 33177133 — intervention group
Group type: COMPARATOR
Intervention: Recreation group
Number of subjects: 111
Study 33177133 — intervention group
Group type: COMPARATOR
Intervention: Usual activity group
Number of subjects: 111
Study 32171511 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated soybean meal (ESBM) diet
Number of subjects: 9
Study 32171511 — intervention group
Group type: COMPARATOR
Intervention: Whey protein concentrate (WPC) diet
Number of subjects: 9
Study 35242595 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 31
Study 35242595 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 31
Study 32176193 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 160
Study 35412873 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (6 mg/kg/dose, twice daily for up to 10 days)
Number of subjects: 130
Study 35412873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 34910312 — intervention group
Group type: EXPERIMENTAL
Intervention: Odiparcil 250 mg twice daily
Number of subjects: 20
Study 34910312 — intervention group
Group type: EXPERIMENTAL
Intervention: Odiparcil 500 mg twice daily
Number of subjects: 20
Study 34910312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32592897 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy during hospitalization, n = 75
Number of subjects: 150
Study 32592897 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving guideline-directed therapy for HF decompensation, n = 75
Number of subjects: 150
Study 34935585 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamnesis interview (experimental group)
Number of subjects: 65
Study 34935585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anamnesis interview)
Number of subjects: 65
Study 33429389 — intervention group
Group type: EXPERIMENTAL
Intervention: CD + T1DM
Number of subjects: 783
Study 33429389 — intervention group
Group type: COMPARATOR
Intervention: CDo
Number of subjects: 783
Study 33429389 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 783
Study 32668476 — intervention group
Group type: EXPERIMENTAL
Intervention: VL10
Number of subjects: 45
Study 32668476 — intervention group
Group type: EXPERIMENTAL
Intervention: VL30
Number of subjects: 45
Study 32668476 — intervention group
Group type: EXPERIMENTAL
Intervention: VL50
Number of subjects: 45
Study 33565676 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support for ACCHS staff
Number of subjects: 70419
Study 33565676 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 70419
Study 32517389 — intervention group
Group type: EXPERIMENTAL
Intervention: USG-ICPB (intermediate cervical plexus block)
Number of subjects: 98
Study 32517389 — intervention group
Group type: COMPARATOR
Intervention: USG-SCPB (superficial cervical plexus block)
Number of subjects: 98
Study 35853675 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg IXE every 4 weeks or 2 weeks
Number of subjects: 932
Study 33455408 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0
Study 33455408 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study 36364802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf powder with 12 mg of 1-deoxynojirimycin (DNJ)
Number of subjects: 0
Study 36364802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf powder extract
Number of subjects: 0
Study 34731076 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐affirmation Implementation Intention
Number of subjects: 454
Study 34731076 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindness Questionnaire
Number of subjects: 454
Study 34731076 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 454
Study 33259721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil scent during heel lancing
Number of subjects: 61
Study 33259721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavender oil scent) during heel lancing
Number of subjects: 61
Study 33285343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional meglumine antimoniate (IL‐MA) administered via subcutaneous injection at approximately 1 mL/cm2 of lesion area once weekly for 1–8 weeks.
Number of subjects: 240
Study 33285343 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meglumine antimoniate (IV‐MA) administered via intravenous injections at a dosage of 10–20 mg Sb5+/kg/day for 20 days.
Number of subjects: 240
Study 36282755 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for 1 hour daily from birth until postnatal week 5
Number of subjects: 116
Study 36282755 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual condition
Number of subjects: 116
Study 34757654 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat yogurt condition
Number of subjects: 96
Study 34757654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat yogurt condition
Number of subjects: 96
Study 34757654 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat/High fat yogurt condition
Number of subjects: 96
Study 34757654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/Low fat yogurt condition
Number of subjects: 96
Study 34757654 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat condition
Number of subjects: 96
Study 34757654 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat and Low fat conditions
Number of subjects: 96
Study 36322838 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide (2.4 mg)
Number of subjects: 201
Study 36322838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 34010748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 30
Study 34010748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32237056 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced‐air warming
Number of subjects: 51
Study 32237056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild intermittent exercise on the bed
Number of subjects: 51
Study 32237056 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 51
Study 33806189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed prostheses supported by 2-4 zygomatic and 2-4 conventional implants
Number of subjects: 80
Study 33806189 — intervention group
Group type: COMPARATOR
Intervention: Fixed prostheses on four implants (all-on-four concept)
Number of subjects: 80
Study 33599706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate radiotherapy (RT) in addition to standard of care (androgen deprivation therapy with or without docetaxel)
Number of subjects: 1939
Study 33599706 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (androgen deprivation therapy with or without docetaxel)
Number of subjects: 1939
Study 32316824 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience intervention
Number of subjects: 92
Study 32316824 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 92
Study 32316824 — intervention group
Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 92
Study 36150662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for diverticulitis
Number of subjects: 243
Study 36150662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for complicated UTI
Number of subjects: 243
Study 36150662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for endocarditis
Number of subjects: 243
Study 33710083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support added to standard case management
Number of subjects: 166
Study 33710083 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 166
Study 33226894 — intervention group
Group type: EXPERIMENTAL
Intervention: Joy Luck Academy (JLA) intervention
Number of subjects: 86
Study 33226894 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 86
Study 33859168 — intervention group
Group type: EXPERIMENTAL
Intervention: T-705
Number of subjects: 145
Study 33859168 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only (Control)
Number of subjects: 145
Study 32014119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 257
Study 32014119 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 257
Study 36176739 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng granules combined with conventional treatment
Number of subjects: 0
Study 36176739 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 0
Study 36209759 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for 7 days
Number of subjects: 300
Study 36209759 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice a day for 14 days
Number of subjects: 300
Study 34463610 — intervention group
Group type: EXPERIMENTAL
Intervention: FP‐SAL (fluticasone propionate plus salmeterol)
Number of subjects: 0
Study 34463610 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 0
Study 37391596 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring in chronic heart failure
Number of subjects: 1450
Study 37391596 — intervention group
Group type: EXPERIMENTAL
Intervention: Data management and transmission of routine data
Number of subjects: 1450
Study 37391596 — intervention group
Group type: EXPERIMENTAL
Intervention: Close communication with SHI funds and intensive data checking
Number of subjects: 1450
Study 34213584 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks (Group B)
Number of subjects: 110
Study 34213584 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin® 500 mg once daily for 4 weeks (Group A)
Number of subjects: 110
Study 32371502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient educational programme
Number of subjects: 300
Study 32371502 — intervention group
Group type: COMPARATOR
Intervention: Standard written and verbal instructions (Control)
Number of subjects: 300
Study 34750297 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEU (in‐utero combination antiretroviral treatment)
Number of subjects: 943
Study 34750297 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEU (Zidovudine alone)
Number of subjects: 943
Study 34750297 — intervention group
Group type: COMPARATOR
Intervention: HUU (control group)
Number of subjects: 943
Study 34750297 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEU (in‐utero exposures to ZDV)
Number of subjects: 943
Study 34769736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic training (theoretical and practical)
Number of subjects: 60